News|Articles|August 10, 2023

GEDi Cube, Renovaro Biosciences Announce Intention to Merge

Companies hope to accelerate fight against cancer

GEDi Cube, an artificial intelligence (AI) company, and Renovaro Biosciences, a pre-clinical biotechnology organization, have revealed an exclusive letter of intent to merge into a single entity. As part of a potential merger, the focus would be on accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases.

"We are rapidly expanding our technologies to include other cancers and diseases," said Craig Rhodes, CEO, GEDi Cube, in a company press release. "I believe that uniting with Renovaro BioSciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”

Reference: AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer. Business Wire. August 9, 2023. Accessed August 10, 2023. https://www.businesswire.com/news/home/20230809952021/en/AI-Company-GEDi-Cube-and-Renovaro-Biosciences-Announce-a-Binding-Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-Cancer


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.